

AUGUST 31, 2016

## STATEMENT ON A NONPROPRIETARY NAME ADOPTED BY THE USAN COUNCIL

USAN (DE-140) SITRAVATINIB

PRONUNCIATION sit'' ra va' ti nib


THERAPEUTIC CLAIM Antineoplastic

## CHEMICAL NAMES

1. 1,1-Cyclopropanedicarboxamide, *N*-[3-fluoro-4-[[2-[5-[[2-(2-methoxyethyl)amino]methyl]-2-pyridinyl]thieno[3,2-*b*]pyridin-7-yl]oxy]phenyl]-*N*-(4-fluorophenyl)-

2. *N*-(3-fluoro-4-[[2-(5-[[2-(2-methoxyethyl)amino]methyl}pyridin-2-yl)thieno[3,2-*b*]pyridin-7-yl]oxy}phenyl)-*N*-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide

## STRUCTURAL FORMULA

MOLECULAR FORMULA  $C_{33}H_{29}F_2N_5O_4S$ 

MOLECULAR WEIGHT 629.7

TRADEMARK None as yet

SPONSOR Mirati Therapeutics

CODE DESIGNATIONS MGCD516

CAS REGISTRY NUMBER 1123837-84-2

UNII CWG62Q1VTB

WHO NUMBER 10216

SCS